<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="134475">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01884779</url>
  </required_header>
  <id_info>
    <org_study_id>ANRS 12260 EDIRAPHIS</org_study_id>
    <nct_id>NCT01884779</nct_id>
  </id_info>
  <brief_title>Prevalence of Histoplasmosis in HIV + Patients With a Rapid Diagnostic Test in West Indies</brief_title>
  <acronym>EDIRAPHIS</acronym>
  <official_title>Histoplasmosis in the Guiana Shield and the French West Indies: Evaluating Prevalence in HIV + Patients With a Rapid Diagnostic Test Using an ELISA Capture Method for the Detection of Histoplasma Antigens in Blood and Urine.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)</source>
  <oversight_info>
    <authority>Suriname:Ministerie van Volksgezondheid</authority>
    <authority>France: Committee for the Protection of Personnes</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Histoplasma capsulatum var. capsulatum histoplasmosis is the leading cause of acquired
      immunodeficiency syndrome (AIDS) and death in French Guiana and probably in the Amazon. The
      diagnosis of this disease requires invasives procedures, laboratory performance, and delays
      up to several weeks. The Mycotic Diseases Branch of the Centers for Disease Control and
      Prevention (CDC) has established a rapid, sensitive and specific ELISA test for blood and
      urine samples that looks interesting in endemic areas, particularly in developing countries.
      The study aims to measure the proportion of HIV-infected patients hospitalized or in
      outpatient awaiting hospitalization for a suspicion of infectious syndrome whose serum
      and/or urinary antigen detection tests are positive for Histoplasma capsulatum var.
      capsulatum.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2013</start_date>
  <completion_date type="Anticipated">July 2015</completion_date>
  <primary_completion_date type="Anticipated">July 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational [Patient Registry]</study_type>
  <study_design>Time Perspective: Cross-Sectional</study_design>
  <target_duration>90 Days</target_duration>
  <primary_outcome>
    <measure>Proportion of HIV-infected patients hospitalized or in outpatient awaiting hospitalization for a suspicion of infectious syndrome whose serum and/or urinary antigen detection tests are positive for Histoplasma capsulatum var. capsulatum.</measure>
    <time_frame>At the time of inclusion (baseline)</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Sensitivity of the ELISA test on urine and blood specimens</measure>
    <time_frame>At the time of inclusion (baseline)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sensibility of the ELISA test on urine and blood specimens</measure>
    <time_frame>At the time of inclusion (baseline)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Negative predictive value of the ELISA test on urine and blood specimens</measure>
    <time_frame>At the time of inclusion (baseline)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of the distribution of Histoplasma antigen concentrations in urine and serum specimens according to severity of cases of histoplasmosis due to Histoplasma capsulatum var. capsulatum</measure>
    <time_frame>At the time of inclusion (baseline)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of the socio-demographic, clinical, paraclinical and therapeutic characteristics according to severity of cases of histoplasmosis due to Histoplasma capsulatum var. capsulatum</measure>
    <time_frame>30 days or 90 days after inclusion</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of the factors for environmental exposure to Histoplasma capsulatum var capsulatum between patients with a positive ELISA test and/or fungal culture for histoplasmosis and those who tested negative for histoplasmosis</measure>
    <time_frame>At the time of inclusion</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of histoplasmosis compared to the other main diagnoses according to three sets of comparisons: positive ELISA test and positive fungal culture; positive ELISA test and negative fungal culture; negative ELISA test and positive fungal culture</measure>
    <time_frame>90 days after inclusion</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of the socio-demographic, clinical, paraclinical, therapeutic and survival outcome characteristics of cases of histoplasmosis compared to those who tested negative for histoplasmosis</measure>
    <time_frame>90 days after inclusion</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Identify the prognostic factors for short-term unfavourable progression of cases of histoplasmosis due to Histoplasma capsulatum  var. capsulatum confirmed by ELISA test and/or by fungal culture</measure>
    <time_frame>30 days and 90 days after inclusion</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">727</enrollment>
  <condition>HIV</condition>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Urine, serum and Histoplasma capsulatum var. capsulatum strains
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Adult (aged 18 or over), seen while hospitalized or in outpatient awaiting
        hospitalization, HIV1 or HIV2 infection confirmed by techniques validated in France and in
        Suriname, either before the episode considered, or discovered concomitantly, and
        presenting at least one of the three followings items: an alteration of their general
        condition (with a grade 1 according to the WHO Performance Status scale) and/or a fever
        and/or symptoms suggestive of an infectious syndrome.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult (aged 18 or over).

          -  Patient seen while hospitalized or in outpatient awaiting hospitalization.

          -  HIV1 or HIV2 infection confirmed by techniques validated in France and in Suriname,
             either before the episode considered, or discovered concomitantly.

          -  Patient presenting at least one of the three followings items: an alteration of their
             general condition (with a grade 1 according to the WHO Performance Status scale)
             and/or a fever and/or symptoms suggestive of an infectious syndrome.

          -  Medical prescription for the collection of blood and urine specimens to test for an
             infectious agent within 7 days following admission to the hospital.

          -  Written consent to participate in the study obtained.

        Exclusion Criteria:

          -  Refusal to participate in the study.

          -  Patient in a critical condition that doesn't allow physicians to get an informed
             consent without a legal representative to represent him and sign a consent form for
             the patient participation in the study.

          -  Ongoing antifungal treatment or antifungal treatment stopped during the month
             preceding the inclusion date (topic antifungal therapy not considered at this point).

          -  Patient in detention at the time of admission to the hospital.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mathieu NACHER, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>CIE 802 Inserm / DGOS</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Stephen G VREDEN, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Foundation for Scientific Research Suriname (SWOS)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mathieu NACHER, MD, PhD</last_name>
    <phone>+594 594 39 50 24</phone>
    <email>mathieu.nacher@ch.cayenne.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Antoine ADENIS, MD, MPH</last_name>
    <phone>+594 594 39 50 08</phone>
    <email>antoine.adenis@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Pointe-à-Pitre University Hospital</name>
      <address>
        <city>Pointe-à-Pitre</city>
        <state>Guadeloupe</state>
        <zip>97159</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Antoine ADENIS, MD, MPH</last_name>
      <phone>+594 594 39 50 08</phone>
      <email>antoine.adenis@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Gilles BEAUCAIRE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cayenne General Hospital</name>
      <address>
        <city>Cayenne</city>
        <state>Guyane</state>
        <zip>97306</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antoine ADENIS, MD, MPH</last_name>
      <phone>+594 594 39 50 08</phone>
      <email>antoine.adenis@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Pierre COUPPIE, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Félix DJOSSOU, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Western French Guiana Hospital</name>
      <address>
        <city>Saint-Laurent-du-Maroni</city>
        <state>Guyane</state>
        <zip>97320</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Antoine ADENIS, MD, MPH</last_name>
      <phone>+594 594 39 50 08</phone>
      <email>antoine.adenis@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Vincent VANTILCKE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fort-de-France University Hospital</name>
      <address>
        <city>Fort-de-France</city>
        <state>Martinique</state>
        <zip>97261</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Antoine ADENIS, MD, MPH</last_name>
      <phone>+594 594 39 50 08</phone>
      <email>antoine.adenis@gmail.com</email>
    </contact>
    <investigator>
      <last_name>André CABIE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Diakonessenhuis hospital</name>
      <address>
        <city>Paramaribo</city>
        <country>Suriname</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sigrid MAC DONALD, MD</last_name>
      <phone>+597 7190800</phone>
      <email>sigi_macdonald@live.com</email>
    </contact>
    <investigator>
      <last_name>Marja VAN EER, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>'s Lands Hospital</name>
      <address>
        <city>Paramaribo</city>
        <country>Suriname</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sigrid MAC DONALD, MD</last_name>
      <phone>+597 7190800</phone>
      <email>sigi_macdonald@live.com</email>
    </contact>
    <investigator>
      <last_name>Aruna JARBANDHAN, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Academisch Ziekenhuis Paramaribo Hospital</name>
      <address>
        <city>Paramaribo</city>
        <country>Suriname</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sigrid MAC DONALD, MD</last_name>
      <phone>+597 7190800</phone>
      <email>sigi_macdonald@live.com</email>
    </contact>
    <investigator>
      <last_name>Stephen G VREDEN, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
    <country>Suriname</country>
  </location_countries>
  <verification_date>October 2013</verification_date>
  <lastchanged_date>October 29, 2013</lastchanged_date>
  <firstreceived_date>June 20, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HIV</keyword>
  <keyword>Histoplasmosis</keyword>
  <keyword>Histoplasma capsulatum var.capsulatum</keyword>
  <keyword>ELISA test</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Histoplasmosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
